A method for delivering a melanocortin-4 receptor agonist to a mammalian subject, includes administering the melanocortin-4 receptor agonist to a tissue inside the nasal cavity or sinuses of the mammalian subject. In some instances, the melanocortin-4 receptor agonist includes a guanidine functional group.

 
Web www.patentalert.com

> Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
~ 00316